# EP2 Antagonists for Ischemic Stroke

> **NIH NIH R61** · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · 2024 · $367,070

## Abstract

PROJECT SUMMARY
Brain ischemia accounts for ~87% acute stroke cases and constitutes a leading cause of deaths in adults and
permanent disabilities among survivors. The current intravenous thrombolysis is the only available medication
for ischemic stroke; mechanical thrombectomy is an emerging alternative treatment for occlusion of large arteries
and has shown promise in selected subsets of patients. However, the overall narrow treatment windows and
potential risks largely limit the patient eligibility. It is thus urgently needed to identify novel drug targets to develop
new, safer, and more effective treatment for ischemic stroke. As the rate-limiting enzyme in biosyntheses of
prostanoids, cyclooxygenase (COX), particularly the inducible isozyme COX-2, has long been implicated in
mechanisms of acute stroke-induced brain injury and inflammation. However, therapeutically targeting COX-2
has been greatly dampened due to unacceptable complications of cardiovascular and cerebrovascular systems
caused by long-term use of COX-2 inhibitors. As a major COX product in the brain, prostaglandin E2 (PGE2) is
elevated by excitotoxic insults and in turn aggravates the neurotoxicity largely via the Gαs-coupled receptor EP2,
inspiring us to target this key pro-inflammatory pathway and to develop bioavailable brain-permeable antagonists
for the EP2 receptor. Recent studies redefined neuropathogenic roles of PGE2/EP2 signaling in ischemic brain
and validated the feasibility of pharmacologically targeting the EP2 receptor for ischemic stroke in mouse model
of middle cerebral artery occlusion (MCAO) using our first-in-class EP2 antagonists. Our overarching goal is to
develop new EP2 antagonists that can be given after cerebral ischemia onset to prevent inflammatory
neuropathology and improve behavioral outcomes. Specifically, utilizing rational design and targeted synthesis,
we will identify novel EP2 antagonists with improved PD, PK, metabolic, and safety profiles (R61 phase). We will
then evaluate therapeutic effects of new EP2 antagonists in multiple animal stroke models (R33 phase).
Successful completion of this project will lead to a proof of concept that EP2 antagonism might represent a novel
strategy to mitigate ischemic injury. Anticipated results will also justify future studies on ADME-Tox, formulation,
off-target activities, efficacy, and more extensive lead-optimization if needed to devise a delayed adjunctive
treatment – along with reperfusion therapy – for brain ischemia.

## Key facts

- **NIH application ID:** 10907027
- **Project number:** 5R61NS130199-02
- **Recipient organization:** UNIVERSITY OF TENNESSEE HEALTH SCI CTR
- **Principal Investigator:** Jianxiong Jiang
- **Activity code:** R61 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $367,070
- **Award type:** 5
- **Project period:** 2023-08-15 → 2026-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10907027

## Citation

> US National Institutes of Health, RePORTER application 10907027, EP2 Antagonists for Ischemic Stroke (5R61NS130199-02). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10907027. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*